Adamas Pharma (ADMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2014 | 12-2013 | 09-2013 | 06-2013 | 03-2013 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,380 | 50,921 | 19,977 | 23,416 | 26,769 |
| Depreciation Amortization | 22 | 66 | 43 | 26 | 11 |
| Accounts receivable | -122 | 761 | 774 | 631 | 16 |
| Accounts payable and accrued liabilities | -2,052 | -1,157 | -1,933 | 176 | -222 |
| Other Working Capital | -2,138 | -29,404 | -31,327 | -28,873 | -30,155 |
| Other Operating Activity | 3,885 | 5,614 | 2,694 | 58 | 646 |
| Operating Cash Flow | $-6,785 | $26,801 | $-9,772 | $-4,566 | $-2,935 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -77 | -167 | -162 | -150 | -46 |
| Investing Cash Flow | $-77 | $-167 | $-162 | $-150 | $-46 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,049 | 21 | 25 | 7 | 3 |
| Other Financing Activity | 0 | -4,000 | -4,000 | -2,280 | -1,420 |
| Financing Cash Flow | $1,049 | $-3,979 | $-3,975 | $-2,273 | $-1,417 |
| Beginning Cash Position | 85,612 | 62,957 | 62,957 | 62,957 | 62,957 |
| End Cash Position | 79,799 | 85,612 | 49,048 | 55,968 | 58,559 |
| Net Cash Flow | $-5,813 | $22,655 | $-13,909 | $-6,989 | $-4,398 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,785 | 26,801 | -9,772 | -4,566 | -2,935 |
| Capital Expenditure | -77 | -167 | -162 | -150 | -46 |
| Free Cash Flow | -6,862 | 26,634 | -9,934 | -4,716 | -2,981 |